Prostate CA Clinical Trials in Nanjing, Jiangsu
22 recruitingNanjing, Jiangsu, China
Showing 1–20 of 22 trials
Recruiting
Phase 2Phase 3
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Prostate Cancer
Novartis Pharmaceuticals443 enrolled72 locationsNCT06780670
Recruiting
Phase 3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled233 locationsNCT06551324
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting
Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled281 locationsNCT06925737
Recruiting
Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Merck Sharp & Dohme LLC1,310 enrolled282 locationsNCT06136624
Recruiting
Phase 3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Prostate Cancer
Novartis Pharmaceuticals940 enrolled55 locationsNCT06855277
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled279 locationsNCT06764485
Recruiting
MR Microstructural Imaging for Prostate Cancer Diagnosis
Prostate CancerDiffusion MRI
First Affiliated Hospital of Zhejiang University2,000 enrolled6 locationsNCT07249281
Recruiting
Phase 2Phase 3
Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer
Prostate CA
baotai Liang83 enrolled1 locationNCT06861192
Recruiting
Phase 2
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
Prostate Cancer
baotai Liang93 enrolled1 locationNCT07163910
Recruiting
Phase 2
Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
Prostate CA
baotai Liang96 enrolled2 locationsNCT06834321
Recruiting
Phase 2
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Metastatic Castration-resistant Prostate Cancer (mCRPC)
MediLink Therapeutics (Suzhou) Co., Ltd.100 enrolled24 locationsNCT06241846
Recruiting
Phase 2
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
Prostate Cancer Metastatic Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School144 enrolled1 locationNCT06992232
Recruiting
High Resolution Diffusion Weighted Imaging in Prostate
Prostate CancerProstate Disease
The First Affiliated Hospital with Nanjing Medical University500 enrolled2 locationsNCT06636747
Recruiting
Phase 3
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Metastatic Prostate CancerTherapy, Directly Observed
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT06350825
Recruiting
Phase 2
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Prostate CancerBiochemical Recurrence
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School102 enrolled2 locationsNCT06305832
Recruiting
Phase 3
Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
Metastatic Prostate CancerIntermitent Anti-androgen Therapy
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT06177015
Recruiting
Phase 3
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
Chemotherapy EffectMetastatic Prostate CancerHormone Sensitive Prostate Cancer
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT05983783
Recruiting
Phase 3
Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The First Affiliated Hospital with Nanjing Medical University100 enrolled1 locationNCT05956639
Recruiting
Phase 2
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Prostate CancerBiochemical Recurrence
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School96 enrolled2 locationsNCT05753566